Welcome to the July 2026 issue of Clinical Thyroidology. It is, of course, true that people’s interests are as varied as there are things to be interested in. For me, I’ve been busy watching the FIFA World Cup that is taking place across the continent of North America. Seeing teams from around the world compete in the “beautiful game” is inspiring and a reminder of how international sport should create a moment of connection that highlights our shared humanity across cultures. Something else we have in common across the globe is the presence of thyroid diseases and dedicated individuals who study and treat them. So, let’s talk about what’s covered in this month’s issue!
We begin again with thyroid cancer and another important summary of 2025 ATA guidelines. In “ATA 2025 DTC Guidelines: De-escalating Therapy and Monitoring,” Dr. Jennifer Mammen reviews areas in the new guidelines that particularly emphasize de-escalation of treatment intensity across multiple areas of thyroid cancer treatment. “Assessing Quality-Adjusted Life-Years for Thyroid Cancer: Development of a Thyroid Cancer–Specific Tool for Health Economic Evaluations” by Dr. Christine O’Neill and Dr. Susanne Singer introduces the Thyroid Cancer Quality of Life Index, a newly developed disease-specific measure designed to capture patient outcomes and support future health economic analyses. Last, Dr. Sana Ghaznavi comments on meta-analysis data about the relative risks and benefits of TSH suppression and how these are incorporated into the changing recommendations for clinical care.
Next is a special guest contribution on thyroid cytology. In “Conventional Smears versus Liquid-Based Cytology in Thyroid Fine-Needle Aspiration: Strengths, Limitations, and Diagnostic Impact,” Dr. Marc Pusztaszeri and Dr. Zubair Baloch compare two widely adopted approaches to thyroid FNA preparation, highlighting that while liquid-based cytology offers advantages in standardization and integration with evolving digital and molecular workflows, conventional smears continue to provide practical strengths, such as the use of rapid on-site evaluation.
On the topic of hypothyroidism, “Dynamic Thyroid Function Assessment May Improve Risk Prediction in MASLD Patients” by Dr. Gabriela Brenta reviews new evidence emphasizing that dynamic assessment of thyroid status may provide greater prognostic value than baseline thyroid function measurements alone when identifying patients at risk for liver-related outcomes in those with metabolic dysfunction–associated steatotic liver disease. Turning to Graves’ disease, “TRAb at Diagnosis and Drug Cessation Predicts Long-Term Relapse Risk after Antithyroid Drug Therapy for Graves’ Thyrotoxicosis,” by Dr. Sarah Brennan, Dr. Venessa Tsang, and Dr. Matti Gild, examines predictors of long-term remission and recurrence, evaluating data that demonstrate TRAb measurements at diagnosis and treatment completion inform relapse risk.
Shifting to thyroid surgery with “Routine versus Selective Calcium Supplementation after Thyroidectomy: Is There a Clear Winner?” Dr. Marika Russell reviews an analysis evaluating routine supplementation versus selective approaches guided by postoperative parathyroid hormone measurement for preventing postoperative hypocalcemia.
We conclude with thyroid nodules. In “A Stroke, a Hematoma, and 60% Volume Reduction: Thyroid Artery Embolization for Large Multinodular Goiters,” Dr. Iram Hussain discusses long-term outcomes following thyroid artery embolization, highlighting reductions in thyroid volume and awareness of procedural risks. Dr. Trisha Cubb, with Dr. Ethan Ruwe and Dr. Alessandra Colaianni, reviews the outcomes of a single session of radiofrequency ablation of benign thyroid nodules from a new analysis in “A Single Radiofrequency Ablation of Benign Thyroid Nodules Demonstrates Durable Effect.” Finally, in “From Pixels to Payer Savings: Balancing Accuracy and Health Care Costs with AI-Adapted Ultrasonography for Thyroid Nodules,” Dr. David Toro-Tobon explores how deep-learning–assisted ultrasound interpretation may influence increased care value by reducing unnecessary biopsies and potentially lowering health care costs.
It is an issue full of exciting new data and insightful perspectives. All are welcome to join us on social media, where we highlight content from each month’s issue to foster greater dialogue and discussion about the latest clinical thyroid literature and other topics related to thyroid health and disorders. Clinical Thyroidology is found at:
As always, we extend a thank you to the editorial board of Clinical Thyroidology for the Public (CTFP), led by Dr. Alan Farwell, for providing freely available lay summaries of our Clinical Thyroidology articles each month, which makes this content accessible to patients and the general public who are interested in learning more about recently published studies in the clinical thyroid literature. CTFP can be found online at https://www.thyroid.org/patient-thyroid-information/ct-for-patients.
I welcome your questions, suggestions, or comments at clinicalthyroidology@thyroid.org.
Please visit the Clinical Thyroidology website to see present and past articles, and enjoy reading.
